Description
What this story covers
Aflac's Q3 2025 10-Q shows $4.7B revenue surge from investment gains, reversing prior losses, with adjusted earnings up to $1.3B. Japan sales rose 14% on cancer products; U.S. premiums grew 4%. Strong liquidity, $3.6B shareholder returns, amid currency and cyber risks.
Story snapshot
CompanyAflac Incorporated
TickerAFL
VariantStandard detailed
Duration12:46
Filing type10-Q
PeriodQ3 2025
IndustryFinancial Services
Accession0001628280-25-049279
Full Story Script
Content not available for this story.
